

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2018202504 B2**

(54) Title  
**Use of long-acting GLP-1 peptides**

(51) International Patent Classification(s)  
**A61K 38/26** (2006.01) **A61P 3/10** (2006.01)  
**A61P 3/04** (2006.01) **A61P 5/50** (2006.01)

(21) Application No: **2018202504** (22) Date of Filing: **2018.04.10**

(43) Publication Date: **2018.05.10**

(43) Publication Journal Date: **2018.05.10**

(44) Accepted Journal Date: **2020.05.07**

(62) Divisional of:  
**2013286177**

(71) Applicant(s)  
**Novo Nordisk A/S**

(72) Inventor(s)  
**Jensen, Christine Bjorn;Rasmussen, Mads Frederik;Zdravkovic, Milan;Kristensen, Peter**

(74) Agent / Attorney  
**Shelston IP Pty Ltd., L 9 60 Margaret St, Sydney, NSW, 2000, AU**

(56) Related Art  
**S. MADSBAD ET AL, "An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future", DIABETES, OBESITY AND METABOLISM, (20110324), vol. 13, no. 5, pages 394 - 407**  
**WO 2010092163 A2**  
**WO 2011138421 A1**  
**Clinical Trial NCT00696657, entitled "A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide," pp. 1-5 (3/11/2015) at URL [clinicaltrials.gov/archive/NCT00696657/2011\\_03\\_25](https://clinicaltrials.gov/archive/NCT00696657/2011_03_25)**